NGeneBio Co

NGeneBio Co Capital Intensity

The Capital Intensity Ratio of NGeneBio Co (354200.KQ) as of Nov 17, 2026 is 340.58 %. In the previous year, Capital Intensity Ratio was 579.00 % — a change of -41.18% (lower).

Capital Intensity

340.58 %

YoY

-41.18%

Last updated:

Capital Intensity Ratio of NGeneBio Co is 2025 340.58 % . Capital Intensity Ratio of NGeneBio Co was 2024 579.00 % . It decreases by -41.18% lower compared to the previous year.

The NGeneBio Co Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
797.66 KRW
Jan 1, 2019
909.55 KRW
Jan 1, 2020
1,992.25 KRW
Jan 1, 2021
612.40 KRW
Jan 1, 2022
509.77 KRW
Jan 1, 2023
971.81 KRW
Jan 1, 2024
579.00 KRW
Jan 1, 2025
340.58 KRW
The NGeneBio Co Capital Intensity history
YEARCapital IntensityYoY
340.58 %-41.18%
579.00 %-40.42%
971.81 %+90.64%
509.77 %-16.76%
612.40 %-69.26%
1,992.25 %+119.04%
909.55 %+14.03%
797.66 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NGeneBio Co Stock analysis

What does NGeneBio Co do? NGeneBio Co., Ltd. generates revenue through the development and sale of diagnostic products for cancer-related genetic testing. The company offers BRCAaccuTest for hereditary breast and ovarian cancer, HEMEaccuTest for blood cancer gene testing including leukemia and lymphoma, and SOLIDaccuTest for solid cancer tissues like lung and colon cancer. Additional products include HLAaccuTest for bone marrow transplantation antigen testing, ONCOaccuPanel for large-capacity solid cancer diagnosis, and HEREDaccuTest for rare disease diagnosis. The firm also provides direct-to-consumer genetic testing and personalized healthcare services, targeting healthcare providers, hospitals, and individual consumers seeking genetic insights. The company's product portfolio serves medical institutions and patients requiring precise genetic diagnostics. HEMEaccuTest specifically addresses blood cancer types such as leukemia and lymphoma, while SOLIDaccuTest covers common solid cancers including lung and stomach cancer. ONCOaccuPanel supports comprehensive solid cancer diagnosis, and HEREDaccuTest caters to rare disease diagnostics. These products are sold to healthcare facilities and offered directly to consumers through DTC services. NGeneBio's revenue streams include sales of diagnostic kits and services, with a focus on cancer-related genetic testing. The BRCAaccuTest, HEMEaccuTest, and SOLIDaccuTest products are central to its business, targeting both clinical and direct consumer markets. Personalized healthcare services complement the product offerings, enhancing customer engagement and recurring revenue opportunities. NGeneBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NGeneBio Co stock

Capital Intensity Ratio of NGeneBio Co is 340.58 % in 2025.

Capital Intensity Ratio of NGeneBio Co changed from 579.00 % to 340.58 %, representing a -41.18% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio NGeneBio Co since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's NGeneBio Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — NGeneBio Co

All Key Metrics — NGeneBio Co